# EDGAR Filing Document

**Accession Number:** 0001698530
**File Stem:** 0001698530-25-000102
**Filing Date:** 2025-11
**Character Count:** 6732
**Document Hash:** 56422e92d0f8fa29b51c2fe2ab816cee
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001698530-25-000102.hdr.sgml**: 20251110

**ACCESSION NUMBER**: 0001698530-25-000102

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251106

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20251110

**DATE AS OF CHANGE**: 20251110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EXICURE, INC.
- **CENTRAL INDEX KEY:** 0001698530
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 815333008
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39011
- **FILM NUMBER:** 251466467

**BUSINESS ADDRESS:**
- **STREET 1:** 2430 N. HALSTED ST.
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60614
- **BUSINESS PHONE:** 847-673-1707

**MAIL ADDRESS:**
- **STREET 1:** 2430 N. HALSTED ST.
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Max-1 Acquisition Corp
- **DATE OF NAME CHANGE:** 20170221

?xml version='1.0' encoding='ASCII'? xcur-20251106

    

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**____________________**

**FORM 8-K**

**____________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 6, 2025**

**____________________**

**Exicure, Inc.**

**(Exact Name of Registrant as Specified in its Charter)**

**____________________**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39011** | **81-5333008** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |

---

---

| | |
|:---|:---|
| **400 Seaport Court, Suite 102** | |
| **Redwood City, CA** | **94063** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (847) 673-1700**

**____________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | XCUR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

    

------

**Item 5.07 &nbsp;&nbsp;&nbsp;&nbsp;Submission of Matters to a Vote of Security Holders.**

On November 6, 2025, Exicure, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following three proposals: (1) to elect the two nominees for Class II directors to hold office until the Company's 2028 Annual Meeting of Stockholders or until their successors are duly elected and qualified ("Proposal 1"), (2) to ratify the selection by the Audit Committee of the Board of Directors of the Company (the "Board") of CBIZ CPAs P.C., as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 ("Proposal 2"), and (3) to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers ("Proposal 3"). The final results of the voting on each proposal are set forth below.

**Proposal 1 - Election of Directors.** 

The Company's stockholders elected the two persons listed below as Class II directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows:

---

| | | |
|:---|:---|:---|
| **Nominee** | **For** | **Withheld** |
| Sangjin Yeo | 3,481,839 | 1,039 |
| Aejin Hwang | 3,481,839 | 1,039 |

---

There were 293,024 broker non-votes with respect to Proposal 1.ere were no abstentions with respect to Proposal 1.

**Proposal 2 - Ratification of the Selection by the Audit Committee of the Board of CBIZ CPAs P.C. as the Independent Registered Public Accounting Firm of the Company for the Fiscal Year Ending December 31, 2025.** 

The Company's stockholders approved Proposal 2. The votes cast were as follows:

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| 3,750,205 | 12,485 | 13,212 |

---

There were no broker non-votes with respect to Proposal 2.

**Proposal 3 - Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.** 

The Company's stockholders approved Proposal 3. The votes cast were as follows:

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| 3,478,408 | 3,931 | 539 |

---

There were 293,024 broker non-votes with respect to Proposal 3.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 104 | Cover Page Interactive Data File (Embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: November 10, 2025 | **EXICURE, INC.** | **EXICURE, INC.** |
|  | (registrant) | (registrant) |
|  | By: | /s/ Andy Yoo |
|  |  | Andy Yoo |
|  |  | Chief Executive Officer |

---